Dr. Jing Yao 姚静
Chief Physician, Associate Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, radiotherapy, targeted therapy, and immunotherapy for breast tumors. Focuses on comprehensive and individualized treatment approaches.
Dr. Jing Yao is a Chief Physician, Associate Professor, and Master’s Supervisor with a medical doctorate. Professional interests include radiochemotherapy and immune molecular targeted therapy for breast cancer.
Professional roles
- Member, Breast Tumor Young Scholars Group, Oncology Branch, Chinese Medical Association
- Member, Breast Cancer Youth Committee, China Anti-Cancer Association
- Member, Clinical Chemotherapy Youth Committee, China Anti-Cancer Association
- Standing Committee Member, Translational Medicine Committee, Hubei Medical Student Biological Immunology Society
Name order: in Chinese the family name comes first (Yao Jing). Papers usually list the name as Jing Yao or Yao J.
Selected publications
29 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Formos Med Assoc, 2026 (senior author): Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy. PubMed 40082190
- Curr Med Sci, 2025 (senior author): Toxicities Associated with Sacituzumab Govitecan: Data from Clinical Trials and a Real-World Pharmacovigilance Database. PubMed 40131630
- Aging (Albany NY), 2020 (senior author): Clinical course and characteristics of patients with coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study. PubMed 32833671
- Breast Cancer Res Treat, 2020 (first author): Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China. PubMed 32594281
- Onco Targets Ther, 2020 (senior author): ERα, A Key Target for Cancer Therapy: A Review. PubMed 32210584
- Onco Targets Ther, 2020 (senior author): Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer. PubMed 32184626
- Cancer Manag Res, 2020 (senior author): The Anti-Cancer Mechanisms of Berberine: A Review. PubMed 32099466
- Onco Targets Ther, 2019 (senior author): Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer. PubMed 31920327
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion